Market Cap (In USD)
863 Million
Revenue (In USD)
237 Thousand
Net Income (In USD)
-184.12 Million
Avg. Volume
15.7 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.64-5.34
- PE
- -5.02
- EPS
- -0.27
- Beta Value
- 0.515
- ISIN
- US3741631036
- CUSIP
- 374163103
- CIK
- 886744
- Shares
- 636904000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. John A. Scarlett M.D.
- Employee Count
- -
- Website
- https://www.geron.com
- Ipo Date
- 1996-07-31
- Details
- Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
More Stocks
-
US37892C1062The Glimpse Group, Inc.
US37892C1062
-
DTLData#3 Limited
DTL
-
PCL
-
300144
-
FCPT
-
PTMN
-
RO
-
KMP-UNKillam Apartment REIT
KMP-UN